 today announced that it has reached an industry milestone with the completion of its 20,000th early-phase clinical study.

This achievement highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology and generic clients.

In conducting 20,000 studies over the past 30 years, Cetero has developed considerable experience with normal healthy participants, special populations, and patients. Cetero currently delivers a 99 percent on-time recruitment rate.

Cetero Completes 20,000th Trial